Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor-κB Ligand in Periodontitis
Umut Balli, Figen Ongoz Dede, Cigdem Coskun Turer, Ahmet Aydogdu, B Güven
article (Uluslararası, Hakemli) | Yazar(lar): Umut Balli, Figen Ongoz Dede, Cigdem Coskun Turer, Ahmet Aydogdu, B Güven | Yıl: 2015 | Dergi/Kurum: JOURNAL OF PERIODONTOLOGY | İndeks: WOS.SCI | DOI: 10.1902/jop.2015.150270 | Anahtar Kelimeler: Gingival crevicular fluid, osteoprotegerin, periodontal diseases, RANK ligand
Background: To investigate changes in the levels and relative ratios of sclerostin, osteoprotegerin (OPG), and receptor activator of nuclear factor-kappa B ligand (RANKL) in the gingival crevicular fluid (GCF) of patients with periodontitis after non-surgical periodontal treatment.
Methods: Fifty-four individuals (27 healthy controls and 27 patients with chronic periodontitis [CP]) were enrolled in the study. Periodontitis patients received non-surgical periodontal therapy. GCF sampling and clinical periodontal parameters were assessed before and 6 weeks after therapy. Sclerostin, OPG, and RANKL levels were measured by enzyme-linked immunosorbent assay, and their relative ratios were calculated.
Results: Total amounts and concentrations of sclerostin were significantly higher in patients with CP than in healthy individuals (P < 0.025) and decreased after treatment (P < 0.05). The RANKL/OPG ratio was significantly lower in healthy individuals than in patients with periodontitis before and after treatment (P < 0.025), but no significant difference was observed in patients with periodontitis after treatment (P > 0.05). The sclerostin/OPG and sclerostin/RANKL ratios were significantly lower in healthy individuals than in patients with periodontitis before and after treatment (P < 0.025) and decreased in patients with periodontitis after treatment (P < 0.05).
Conclusions: The GCF sclerostin level may be more reliable than the RANKL/OPG ratio as a diagnostic and prognostic marker of periodontal disease and treatment outcome. Regulation of sclerostin levels may aid the development of new therapeutic strategies for the treatment of periodontal disease.